Arcutis Biotherapeutics financials at a glance

+ Portfolio

The revenue of Arcutis Biotherapeutics is reported as 0.05961 billion Dollars in the fiscal year 2023. The earnings were -3.78 Dollars per share in 2023, which was 33.22 higher than 2022. And about -0.00032 billion Dollars are reported as free cash flow in the financials of Arcutis Biotherapeutics 2023. No dividends were paid to the shareholders of the Arcutis Biotherapeutics stock NasdaqGS:ARQT in the financial year 2023.

$59.61M

Revenue

$-3.78

Earnings Per Share

91.63%

Gross Margin %

$-,206.00M

Free Cash Flow

Revenue

59.61

Earnings Per Share

-3.78

Gross Margin %

91.63

Free Cash Flow

-,206.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019
Rev.	Revenue	N/A	$59.61M	$3.69M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	93.42%	91.63%	79.54%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-4.37	$-3.78	$-5.66	$-4.18	$-3.80	$-22.78
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	0	0	0
Sha.	Shares	N/AM	96.81M	61.08M	50.38M	50.08M	37.95M
OCF	Operating Cash Flow	N/A	$0.00M	$-,257.72M	$-,174.63M	$-,113.03M	$-42.84M
FCF	Free Cash Flow	N/A	$-,206.00M	$-,258.05M	$-,175.62M	$-,113.35M	$-43.13M
FCFS	Free Cash Flow Per Share	$-4.28	$-3.57	$-5.11	$-3.55	$-3.18	$-23.40

Arcutis Biotherapeutics financials at a glance

Financials

Discover